Currently Viewing:
Supplements Exploring the Evolving Landscape of Precision Medicine
Recognizing the Value of Precision Medicine: Oncology and Beyond
Marina Reed, 2020 PharmD Candidate, and Michael R. Page, PharmD, RPh
Aligning Incentives: Quality of Care Initiatives and Precision Medicine
Keren Freydman, 2018 PharmD Candidate and Michael R. Page, PharmD, RPh
Regulations That Ensure the Quality of Precision Medicine
Xi Xu, 2018 PharmD Candidate, and Michael R. Page, PharmD, RPh
Personalized Medicine and Clinical Trials: A Q&A With Apostolia M. Tsimberidou, MD, PhD
Currently Reading
The Importance of Registries in the Personalized Medicine Revolution: A Q&A With the President of CURE-1, Dane Dickson, MD
The Pharmacogenomic View of Precision Medicine: A Q&A With Howard McLeod, PharmD
Participating Faculty

The Importance of Registries in the Personalized Medicine Revolution: A Q&A With the President of CURE-1, Dane Dickson, MD

AJMC®: Finally, what would you say would be the most important takeaways for payers in terms of understanding the future of personalized medicine and how their coverage policies are ultimately going to change as a result of everything that is happening in personalized medicine over the next few years?

Dickson: Payers have more control than they will ever know about how medicine evolves in this nation. And truly, payers have the ability to embrace precision medicine that ultimately can lead to decreased cost and better quality of care. But what it is going to require is that payers really take an active and not a passive role in determining the evolution of precision medicine. Payers can look at their policies and think about introducing precision medicine sooner rather than later in certain areas where we know it is beneficial, such as in lung cancer patients, but if they are going to do that, they need to make sure that the laboratory is a good-quality laboratory and that they are participating in further data-collection efforts. Without those further data efforts, we are never going to get further answers. The payers need to support not only precision medicine but also support standards and data collection—not because it’s experimental but because it’s important as part of driving the information that will be necessary to get where we want to go. And so the payers need to be a key portion of that and be involved in helping drive for those standards and the data collection that is going to be so important to reduce cost and improve care for patients.

PDF
 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!